Literature DB >> 36099148

Evaluation of CD4+:CD8+ Ratio in Patients With Cervical Cancer and the Levels of Inflammatory Markers.

Magdi M Salih1, Mazen Almehmadi2, Alaa Shafie2, Abdulaziz Alsharif2, Naif Alsiwiehri2, Ahmad El-Askary2, Khalid Alzahrani2, Abdulelah Aljuaid2, Osama Abdulaziz2, Amani Ahmed Alrehaili2, Abdulraheem A Almalki2, Hassan Swed Alzahrani3, Mustafa Halawi4, Safar Almalki3, Ebtisam Alosimi2, Amal F Gharib2.   

Abstract

BACKGROUND/AIM: Cervical cancer remains a major public health concern. The ratio of CD4+:CD8+ T-cells is used to evaluate the immune system function. This study aimed to explore the CD4+:CD8+ T-cell ratio in relation to the glycemic status, inflammatory markers, vitamin D, and vitamin B12 in patients with early diagnosed cervical cancer. PATIENTS AND METHODS: This is a cross-sectional study. Blood samples were collected for flow cytometry analysis. Information regarding Papanicolaou (Pap) smears and colposcopy investigations were collected from 152 women with type 2 diabetes admitted to East Jeddah Hospital, Jeddah, Saudi Arabia, between January 2018 and January 2021.
RESULTS: Patients with early cervical carcinoma and a higher CD4+:CD8+ ratio (>1.2) had a higher C-reactive protein (CRP) level than those with a lower CD4+:CD8+ ratio (Mean±SD=13.75±13.3 vs. 10.85±8.1; p-value=0.034). Patients with early cervical carcinoma, diabetes, and higher CD4+:CD8+ ratio (>1.2) had a higher blood HbA1c percent than those with a lower CD4+:CD8+ ratio.
CONCLUSION: A high CD4+:CD8+ T-cells ratio was associated with an increased HbA1c% and CRP levels in women with diabetes diagnosed with early cervical carcinoma, which can induce inflammation in early diagnosed patients with cervical cancer.
Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  C-Reactive protein; Cervical cancer; diabetic women; early cervical carcinoma

Mesh:

Substances:

Year:  2022        PMID: 36099148      PMCID: PMC9463885          DOI: 10.21873/invivo.12975

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.406


  37 in total

Review 1.  Cytokines in inflammatory bowel disease.

Authors:  Markus F Neurath
Journal:  Nat Rev Immunol       Date:  2014-04-22       Impact factor: 53.106

2.  Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.

Authors:  Claudia Nunes; Ryan Wong; Malcolm Mason; Chris Fegan; Stephen Man; Chris Pepper
Journal:  Clin Cancer Res       Date:  2011-12-21       Impact factor: 12.531

3.  Effects of Long-Term Vitamin D Supplementation on Regression and Metabolic Status of Cervical Intraepithelial Neoplasia: a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Zahra Vahedpoor; Mehri Jamilian; Fereshteh Bahmani; Esmat Aghadavod; Maryam Karamali; Maryam Kashanian; Zatollah Asemi
Journal:  Horm Cancer       Date:  2017-01-03       Impact factor: 3.869

4.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

Authors:  Silvia de Sanjose; Wim Gv Quint; Laia Alemany; Daan T Geraets; Jo Ellen Klaustermeier; Belen Lloveras; Sara Tous; Ana Felix; Luis Eduardo Bravo; Hai-Rim Shin; Carlos S Vallejos; Patricia Alonso de Ruiz; Marcus Aurelho Lima; Nuria Guimera; Omar Clavero; Maria Alejo; Antonio Llombart-Bosch; Chou Cheng-Yang; Silvio Alejandro Tatti; Elena Kasamatsu; Ermina Iljazovic; Michael Odida; Rodrigo Prado; Muhieddine Seoud; Magdalena Grce; Alp Usubutun; Asha Jain; Gustavo Adolfo Hernandez Suarez; Luis Estuardo Lombardi; Aekunbiola Banjo; Clara Menéndez; Efrén Javier Domingo; Julio Velasco; Ashrafun Nessa; Saibua C Bunnag Chichareon; You Lin Qiao; Enrique Lerma; Suzanne M Garland; Toshiyuki Sasagawa; Annabelle Ferrera; Doudja Hammouda; Luciano Mariani; Adela Pelayo; Ivo Steiner; Esther Oliva; Chris Jlm Meijer; Waleed Fahad Al-Jassar; Eugenia Cruz; Thomas C Wright; Ana Puras; Cecilia Ladines Llave; Maria Tzardi; Theodoros Agorastos; Victoria Garcia-Barriola; Christine Clavel; Jaume Ordi; Miguel Andújar; Xavier Castellsagué; Gloria I Sánchez; Andrzej Marcin Nowakowski; Jacob Bornstein; Nubia Muñoz; F Xavier Bosch
Journal:  Lancet Oncol       Date:  2010-10-15       Impact factor: 41.316

Review 5.  Activated T lymphocytes in Type 2 diabetes: implications from in vitro studies.

Authors:  Frankie B Stentz; Abbas E Kitabchi
Journal:  Curr Drug Targets       Date:  2003-08       Impact factor: 3.465

6.  C-reactive protein is a prognostic parameter in patients with cervical cancer.

Authors:  Stephan Polterauer; Christoph Grimm; Clemens Tempfer; Gerhard Sliutz; Paul Speiser; Alexander Reinthaller; Lukas A Hefler
Journal:  Gynecol Oncol       Date:  2007-07-06       Impact factor: 5.482

7.  Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival.

Authors:  Bridget A Quinn; Xiaoyan Deng; Adrianne Colton; Dipankar Bandyopadhyay; Jori S Carter; Emma C Fields
Journal:  Brachytherapy       Date:  2018-10-22       Impact factor: 2.362

8.  Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer.

Authors:  Maximilian Schmid; Alois Schneitter; Stefan Hinterberger; Julia Seeber; Alexander Reinthaller; Lukas Hefler
Journal:  Obstet Gynecol       Date:  2007-12       Impact factor: 7.661

9.  Prognostic Values of Systemic Inflammation Response (SIR) Parameters in Resectable Cervical Cancer.

Authors:  Wen-Jie Wang; Ying Li; Jie Zhu; Min-Jie Gao; Jian-Ping Shi; Yue-Qing Huang
Journal:  Dose Response       Date:  2019-02-26       Impact factor: 2.658

10.  Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.

Authors:  Esma Karkeni; Stéphanie O Morin; Berna Bou Tayeh; Armelle Goubard; Emmanuelle Josselin; Rémy Castellano; Cyril Fauriat; Geoffrey Guittard; Daniel Olive; Jacques A Nunès
Journal:  Front Immunol       Date:  2019-06-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.